Sage Therapeutics Inc.

NAS: SAGE

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Sage Therapeutics Inc.

Before the Bell

--Real time quotes

Dec 1, 2023, 9:10 a.m.

SAGE

/zigman2/quotes/200179567/composite

20.11

Change

+0.53 +2.71%

Volume

Volume 104

Real time quotes

/zigman2/quotes/200179567/composite

Previous close

$ 19.58

Change

+0.10 +0.51%

Day low

Day high

$19.46

$20.16

52 week low

52 week high

$16.52

$59.99

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Sage Therapeutics Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	90.27M	6.87M	1.11B	6.31M	7.69M
Sales Growth	-	-92.39%	16,123.06%	-99.43%	21.85%
Cost of Goods Sold (COGS) incl. D&A	1.1M	2.68M	3.2M	4.74M	1.94M
COGS excluding D&A	-	400,000	565,000	553,000	813,000
Depreciation & Amortization Expense	1.1M	2.28M	2.63M	4.18M	1.12M
Depreciation	1.1M	2.28M	2.63M	4.18M	1.12M
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	143.91%	19.08%	48.20%	-59.13%
Gross Income	89.17M	4.19M	1.11B	1.57M	5.75M
Gross Income Growth	-	-95.31%	26,447.31%	-99.86%	265.61%
Gross Profit Margin	-	-	-	-	74.82%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	482.41M	712.31M	487.04M	462.48M	552.74M
Research & Development	282.11M	368.82M	292.71M	283.17M	326.16M
Other SG&A	200.3M	343.49M	194.32M	179.32M	226.58M
SGA Growth	-	47.66%	-31.63%	-5.04%	19.52%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	27.74M	-	-
EBIT after Unusual Expense	-	-	596.23M	-	-
Non Operating Income/Expense	22,000	82,000	250,000	134,000	15,000
Non-Operating Interest Income	20.33M	27.8M	9.6M	2.88M	14.19M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	-	-	-
Interest Expense Growth	-	-	-	-	-
Gross Interest Expense	-	-	-	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(372.88M)	(680.24M)	606.07M	(457.89M)	(532.78M)
Pretax Income Growth	-	-82.43%	189.10%	-175.55%	-16.36%
Pretax Margin	-	-	-	-	-6,931.88%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(372.88M)	(680.24M)	606.07M	(457.89M)	(532.78M)
Minority Interest Expense	-	-	-	-	-
Net Income	(372.88M)	(680.24M)	606.07M	(457.89M)	(532.78M)
Net Income Growth	-	-82.43%	189.10%	-175.55%	-16.36%
Net Margin Growth	-	-	-	-	-6,931.88%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(372.88M)	(680.24M)	606.07M	(457.89M)	(532.78M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(372.88M)	(680.24M)	606.07M	(457.89M)	(532.78M)
EPS (Basic)	(8.08)	(13.38)	11.66	(7.80)	(8.98)
EPS (Basic) Growth	-	-65.52%	187.13%	-166.94%	-15.11%
Basic Shares Outstanding	46.12M	50.83M	51.98M	58.67M	59.31M
EPS (Diluted)	(8.08)	(13.38)	11.43	(7.80)	(8.98)
EPS (Diluted) Growth	-	-65.52%	185.45%	-168.25%	-15.11%
Diluted Shares Outstanding	46.12M	50.83M	53M	58.67M	59.31M
EBITDA	(392.14M)	(705.84M)	626.6M	(456.73M)	(545.87M)
EBITDA Growth	-	-80.00%	188.77%	-172.89%	-19.52%
EBITDA Margin	-	-	-	-	-7,102.09%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Sage Therapeutics Inc.

Annual Financials for Sage Therapeutics Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk